The Race Is on for These Two Dividend ETFs. Which Is Best for You?
With a mere $1 billion gap in the way, SCHD is about to dethrone VIG. But bigger isn’t always better.
Moderna Leads the Charge as Pharma ETF Hits All-Time High
Tempus AI and Merck are key contributors to Moderna’s success.
Weekly Roundup: A Hot Start to August as Portfolio Catches a Wave
We added three new holdings this week, diversifying our lineup, and locked in massive gains across three others.
Market Indecision: War Uncertainty, Wacky Econ Data, Fake News?
Investors are stuck dealing with more questions over the state of the Strait, economic data that doesn’t quite make sense, and accusations of fake news.
We’re Initiating New Positions in 2 ETFs
Following our cybersecurity strategy, we’re bringing new end-market exposures to the Portfolio.
Who Wants to Believe in Iran Talks? (The Markets Do); Big Earnings; Yen Plan
Let’s look at how Trump holds off big attack on Iran and the markets look optimistic, a joint plan for the yen, and earnings on tap for this week.
A Classic Washout and More Mixed Reactions to Earnings
Amazon is up and Apple is down after their reports.
Mag 7 Action Improves, But Biotech Keeps Delivering the Real Wins
While reverse rotation drives Nasdaq bounce, poor breadth suggests it can’t be trusted.
‘Strait’ of Confusion, Black Eye for Bezos’ Blue Origin, Sell … in May?
Iran deal is reportedly near, again …; Blue Origin proves ‘rockets are hard’ and remember what the say about May? Well…